Chimerix, Inc. announced on Friday that it is halting research and development into their potential vaccine against the Ebola virus.
Following a discussion with the Food and Drug Administration (FDA) the company decided that with the cases of new Ebola virus infections decreasing in Liberia the company's resources would be better utilized in utilizing this vaccine toward other viral infections.
They also state that they will no longer participate in the studies or clinical trials in using their brincidofovir compound to be used for Ebola, including the one conducted by Oxford University in Liberia that was announced in Dec. 2014.
The compound is intended to continue clinical trials to be utilized against other viral infections, including the cytomegalovirus and the adenovirus.
"We were honored to be able to work with the researchers at University of Oxford and ISARIC together with MSF to initiate the first clinical trial of an investigational agent during an outbreak. The progress in controlling the Ebola outbreak in Liberia is to be commended," said Dr. M. Michelle Berrey, president and CEO of Chimerix. "Chimerix will continue to push forward with our development of brincidofovir for the prevention and treatment of serious viral infections in transplant recipients and other immunocompromised patients."